Search

Your search keyword '"Gavasso, S"' showing total 409 results
Start Over Author "Gavasso, S"
409 results on '"Gavasso, S"'

56. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis

Author

PAOLO SIMIONI, Prandoni, P., Lensing, A. W. A., Manfrin, D., Tormene, D., Gavasso, S., Girolami, B., Sardella, C., Prins, M., Girolami, A., Infectious diseases, AII - Amsterdam institute for Infection and Immunity, and APH - Amsterdam Public Health

Subjects
Adult, Aged, 80 and over, Male, Venous Thrombosis, Heterozygote, Immunology, Factor V, Cell Biology, Hematology, Middle Aged, Biochemistry, Cohort Studies, Recurrence, Risk Factors, Thromboembolism, Mutation, Prevalence, Humans, Female, Prothrombin, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Carriers of a mutation in the prothrombin (clotting factor II) or factor V gene have a 2- to 4-fold greater risk for venous thromboembolism than subjects without the mutations. Whether both mutations also predispose to recurrent venous thromboembolism is unclear. Outpatients who had a first episode of proven symptomatic deep-vein thrombosis and a long-term follow-up were studied. The outcome measure was the cumulative incidence of confirmed venous thromboembolic complications. Two hundred fifty-one patients were enrolled in the study. Mean duration of follow-up was 8.3 years. The prothrombin gene mutation was demonstrated in 27 patients (prevalence, 10.8%; 95% CI, 6.9 to 14.6), and the factor V gene mutation was demonstrated in 41 patients (prevalence, 16.3%; 95% CI, 11.8 to 20.9). The cumulative incidence of venous thromboembolic complications after 10 years was 61.3% (95% CI, 35.7 to 87.9), and the hazard ratio was 2.4 (95% CI, 1.3 to 4.7; P = .004) in patients with the prothrombin gene mutation); the cumulative incidence of venous thromboembolic complications after 10 years was 55.2% (95% CI, 36.4 to 74.0), and the hazard ratio was 2.4 (95% CI, 1.4 to 4.1;P = .001) in patients with the factor V gene mutation. In comparison, the cumulative incidence of venous thromboembolic complications after 10 years was 23.1% (95% CI, 16.2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications

Published
2000

58. Whole Blood Coagulation Tests are not Equally able to Detect Haemostatic Prothrombotic Alterations in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Rotational Thromboelastometry versus Thrombingeneration Test

Author

Zanetto, A., primary, Ferrarese, A., additional, Nadal, E., additional, Bortoluzzi, I., additional, Campello, E., additional, Spiezia, L., additional, Cillo, U., additional, Vitale, A., additional, Farinati, F., additional, Germani, G., additional, Russo, F.P., additional, Gavasso, S., additional, Simioni, P., additional, Burra, P., additional, and Senzolo, M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results